(Q37861583)

24 August 2017

1 reference

title

Mineralocorticoid receptor blockade in chronic kidney disease (English)

1 reference

24 August 2017

Matthew J Volk

1

1 reference

24 August 2017

Andrew S Bomback

series ordinal

2

1 reference

24 August 2017

Philip J Klemmer

series ordinal

3

1 reference

24 August 2017

publication date

1 August 2011

1 reference

Current Hypertension Reports

24 August 2017

published in

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

282-288

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-011-0202-2

24 August 2017

exact match

0 references

cites work

The incidence and implications of aldosterone breakthrough

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "no-salt" culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Essential hypertension: renin and aldosterone, heart attack and stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Disordered aldosterone-volume relationship in end-stage kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldosterone: role in the cardiometabolic syndrome and resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Role of aldosterone in the remnant kidney model in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Benefits of dietary sodium restriction in the management of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Role of excess volume in the pathophysiology of hypertension in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Bioimpedance analysis in dialysis: state of the art and what we can expect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Importance of whole-body bioimpedance spectroscopy for the management of fluid balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Molecular mechanisms of human hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Sleep apnea, aldosterone, and resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Association of adrenal steroids with hypertension and the metabolic syndrome in blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldosterone contributes to blood pressure variance and to likelihood of hypertension in normal-weight and overweight African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Extracellular volume and aldosterone interaction in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Disorders of body fluids, sodium and potassium in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

The association between left ventricular hypertrophy and biomarkers in patients on continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Peritoneal mesothelial cells as a target of local aldosterone action: upregulation of connective tissue growth factor expression via serum- and glucocorticoid-inducible protein kinase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Is spironolactone safe for dialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Safety of low-dose spironolactone administration in chronic haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldactone therapy in a peritoneal dialysis patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

A fresh look at dry weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Single-Channel and Whole-Cell Currents Evoked by Acetylcholine in Dissociated Sympathetic Neurons of the Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0202-2

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

12 December 2020

Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action

1 reference

12 December 2020

Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism

1 reference

12 December 2020

The role of aldosterone in potassium tolerance: studies in anephric humans

1 reference

12 December 2020

Plasma aldosterone concentrations in chronic renal disease

1 reference

12 December 2020

Single-channel and whole-cell currents evoked by acetylcholine in dissociated sympathetic neurons of the rat.

1 reference

12 December 2020

Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors

1 reference

12 December 2020

Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis

1 reference

12 December 2020

Spironolactone in chronic hemodialysis patients improves cardiac function.

1 reference

12 December 2020

Rise in extracellular fluid volume during high sodium depends on BMI in healthy men

1 reference

12 December 2020

Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure.

1 reference

12 December 2020

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

12 December 2020

10.1007/S11906-011-0202-2

Identifiers

DOI

1 reference

24 August 2017

1 reference